Quebec pharmacists across the province say they are struggling to meet the demand for semaglutides, the active ingredient in the popular drug Ozempic. The shortage affects generic versions of the medication, which is used to manage type 2 diabetes and, increasingly, for weight loss.
Rising Demand Outstrips Supply
Pharmacists report that the surge in demand for semaglutides has outpaced supply, leaving many patients without access to the medication. The issue is particularly acute for those relying on generic formulations, which are often more affordable than brand-name Ozempic.
Impact on Patients
Patients with diabetes who depend on semaglutides for blood sugar control are facing disruptions in their treatment plans. Some have been forced to switch to alternative medications, which may not be as effective or could cause side effects.
Healthcare providers are advising patients to consult with their doctors about potential alternatives and to avoid purchasing medications from unverified sources, as counterfeit products pose serious health risks.
Calls for Action
Pharmacy associations are urging the Quebec government and Health Canada to address the shortage by increasing production capacity and streamlining import regulations. They also emphasize the need for better forecasting and communication between manufacturers, regulators, and healthcare providers to prevent future shortages.
In the meantime, pharmacists are working to manage existing supplies equitably, prioritizing patients with the most urgent medical needs.
